IBDEI1K9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24946,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,24946,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,24946,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,24947,0)
 ;;=Z85.79^^107^1212^88
 ;;^UTILITY(U,$J,358.3,24947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24947,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,24947,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,24947,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,24948,0)
 ;;=Z85.820^^107^1212^77
 ;;^UTILITY(U,$J,358.3,24948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24948,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,24948,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,24948,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,24949,0)
 ;;=Z85.828^^107^1212^92
 ;;^UTILITY(U,$J,358.3,24949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24949,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,24949,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,24949,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,24950,0)
 ;;=Z85.71^^107^1212^72
 ;;^UTILITY(U,$J,358.3,24950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24950,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,24950,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,24950,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,24951,0)
 ;;=Z65.8^^107^1212^144
 ;;^UTILITY(U,$J,358.3,24951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24951,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,24951,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,24951,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,24952,0)
 ;;=Z86.11^^107^1212^109
 ;;^UTILITY(U,$J,358.3,24952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24952,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,24952,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,24952,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,24953,0)
 ;;=Z86.13^^107^1212^76
 ;;^UTILITY(U,$J,358.3,24953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24953,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,24953,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,24953,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,24954,0)
 ;;=Z86.73^^107^1212^106
 ;;^UTILITY(U,$J,358.3,24954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24954,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,24954,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,24954,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,24955,0)
 ;;=Z86.79^^107^1212^69
 ;;^UTILITY(U,$J,358.3,24955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24955,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,24955,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,24955,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,24956,0)
 ;;=Z91.040^^107^1212^57
 ;;^UTILITY(U,$J,358.3,24956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24956,1,3,0)
 ;;=3^Latex Allergy Status
 ;;^UTILITY(U,$J,358.3,24956,1,4,0)
 ;;=4^Z91.040
 ;;^UTILITY(U,$J,358.3,24956,2)
 ;;=^5063607
 ;;^UTILITY(U,$J,358.3,24957,0)
 ;;=Z92.3^^107^1212^73
 ;;^UTILITY(U,$J,358.3,24957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24957,1,3,0)
 ;;=3^Personal Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,24957,1,4,0)
 ;;=4^Z92.3
 ;;^UTILITY(U,$J,358.3,24957,2)
 ;;=^5063637
 ;;^UTILITY(U,$J,358.3,24958,0)
 ;;=Z91.120^^107^1212^53
